阳性结果-话题@MedSci

#阳性结果#

49篇内容 | 2075人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1642065, encodeId=252b164206511, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, objectType=article, longId=192022, objectId=d2621920220a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2621920220a, replyNumber=0, likeNumber=62, createdTime=2020-12-16, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2621920220a, moduleTitle=RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2621920220a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642046, encodeId=bca6164204667, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=喜大普奔 | III期FLAURA 研究OS取得阳性结果，EGFR突变晚期非小细胞肺癌一线标准治疗已成定论, objectType=article, longId=177574, objectId=06bb1e7574a5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=06bb1e7574a5, replyNumber=0, likeNumber=99, createdTime=2019-11-17, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=06bb1e7574a5, moduleTitle=喜大普奔 | III期FLAURA 研究OS取得阳性结果，EGFR突变晚期非小细胞肺癌一线标准治疗已成定论, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=06bb1e7574a5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642066, encodeId=b80816420667f, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, objectType=article, longId=196814, objectId=693e19681493, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=693e19681493, replyNumber=0, likeNumber=53, createdTime=2021-01-31, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=693e19681493, moduleTitle=Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=693e19681493)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642049, encodeId=ab7d164204957, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果, objectType=article, longId=179522, objectId=8c931e952273, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c931e952273, replyNumber=0, likeNumber=61, createdTime=2020-04-13, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c931e952273, moduleTitle=Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c931e952273)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642055, encodeId=239816420559c, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=Biogen宣布BDCA2单抗BIIB059在皮肤性红斑狼疮和系统性红斑狼疮的2期研究阳性结果, objectType=article, longId=184168, objectId=6fdd184168d5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6fdd184168d5, replyNumber=0, likeNumber=64, createdTime=2020-11-10, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6fdd184168d5, moduleTitle=Biogen宣布BDCA2单抗BIIB059在皮肤性红斑狼疮和系统性红斑狼疮的2期研究阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6fdd184168d5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642058, encodeId=9126164205874, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=Kadimastem报告其针对渐冻症的干细胞疗法阳性结果, objectType=article, longId=185639, objectId=b77c1856392d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b77c1856392d, replyNumber=0, likeNumber=0, createdTime=2020-02-10, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b77c1856392d, moduleTitle=Kadimastem报告其针对渐冻症的干细胞疗法阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b77c1856392d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642063, encodeId=c0231642063c1, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=Antolimab（AK002）治疗肥大细胞胃肠道疾病：I期阳性结果, objectType=article, longId=190836, objectId=3f35190836d8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3f35190836d8, replyNumber=0, likeNumber=68, createdTime=2020-04-20, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3f35190836d8, moduleTitle=Antolimab（AK002）治疗肥大细胞胃肠道疾病：I期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3f35190836d8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642053, encodeId=bfe016420537b, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=赛诺菲公布其长效胰岛素Toujeo治疗青少年糖尿病的3期阳性结果, objectType=article, longId=182392, objectId=dc5618239254, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=dc5618239254, replyNumber=0, likeNumber=58, createdTime=2019-11-29, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=dc5618239254, moduleTitle=赛诺菲公布其长效胰岛素Toujeo治疗青少年糖尿病的3期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=dc5618239254)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642051, encodeId=5b21164205192, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果, objectType=article, longId=180608, objectId=b0ed180608a6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b0ed180608a6, replyNumber=0, likeNumber=65, createdTime=2020-07-18, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b0ed180608a6, moduleTitle=诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b0ed180608a6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642041, encodeId=310f16420411c, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=JAMA：阳性结果的文章，一定更受关注吗？, objectType=article, longId=166399, objectId=6a4116639924, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6a4116639924, replyNumber=0, likeNumber=62, createdTime=2020-02-15, rootId=0, userName=heli0118, userId=21015, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6a4116639924, moduleTitle=JAMA：阳性结果的文章，一定更受关注吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6a4116639924)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642054, encodeId=b02f164205401, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=2019年美国心脏协会科学会议：细胞疗法CLBS16治疗冠状动脉微血管功能障碍取得阳性结果, objectType=article, longId=183161, objectId=d4a6183161dd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4a6183161dd, replyNumber=0, likeNumber=70, createdTime=2020-04-06, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4a6183161dd, moduleTitle=2019年美国心脏协会科学会议：细胞疗法CLBS16治疗冠状动脉微血管功能障碍取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4a6183161dd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642047, encodeId=01d3164204e8f, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=阳性结果促使埃博拉临床试验提前停止, objectType=article, longId=177609, objectId=f4401e760965, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f4401e760965, replyNumber=0, likeNumber=66, createdTime=2020-06-21, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f4401e760965, moduleTitle=阳性结果促使埃博拉临床试验提前停止, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f4401e760965)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642042, encodeId=d17d164204221, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=AP&T：使用基于粪便细菌标记物的特征的检测手法可减少粪便免疫化学测试假阳性结果, objectType=article, longId=166404, objectId=d034166404c7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d034166404c7, replyNumber=0, likeNumber=67, createdTime=2019-12-02, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d034166404c7, moduleTitle=AP&T：使用基于粪便细菌标记物的特征的检测手法可减少粪便免疫化学测试假阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d034166404c7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642043, encodeId=6e8e164204326, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=Kyowa Hakko Kirin公布其白细胞介素-17受体A单抗brodalumab治疗轴性脊柱关节炎患者的临床3期阳性结果, objectType=article, longId=168718, objectId=1557168e1835, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1557168e1835, replyNumber=0, likeNumber=104, createdTime=2020-01-31, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1557168e1835, moduleTitle=Kyowa Hakko Kirin公布其白细胞介素-17受体A单抗brodalumab治疗轴性脊柱关节炎患者的临床3期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1557168e1835)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642048, encodeId=1dd1164204896, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=Terns宣布其血管粘附蛋白-1抑制剂TERN-201治疗非酒精性脂肪性肝炎的I期临床中期阳性结果, objectType=article, longId=177617, objectId=12b31e761746, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=12b31e761746, replyNumber=0, likeNumber=69, createdTime=2020-01-20, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=12b31e761746, moduleTitle=Terns宣布其血管粘附蛋白-1抑制剂TERN-201治疗非酒精性脂肪性肝炎的I期临床中期阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=12b31e761746)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642040, encodeId=d356164204007, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, objectType=article, longId=166254, objectId=0b72166254e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0b72166254e3, replyNumber=0, likeNumber=71, createdTime=2019-10-26, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0b72166254e3, moduleTitle=辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0b72166254e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642038, encodeId=c3ca164203899, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果, objectType=article, longId=156671, objectId=78e61566e182, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=78e61566e182, replyNumber=0, likeNumber=84, createdTime=2019-07-01, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=78e61566e182, moduleTitle=XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=78e61566e182)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642050, encodeId=7400164205099, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=安进宣布两项三期双特异性抗体BLINCYTO（靶向CD3和CD19）治疗小儿复发性急性淋巴细胞白血病患者的阳性结果, objectType=article, longId=180054, objectId=6917180054ef, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6917180054ef, replyNumber=0, likeNumber=0, createdTime=2020-01-18, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6917180054ef, moduleTitle=安进宣布两项三期双特异性抗体BLINCYTO（靶向CD3和CD19）治疗小儿复发性急性淋巴细胞白血病患者的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6917180054ef)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642044, encodeId=89cf164204491, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=肌层浸润性膀胱癌的治疗：TAR-200在Ib期试验中的阳性结果, objectType=article, longId=174335, objectId=93c21e43356e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=93c21e43356e, replyNumber=0, likeNumber=65, createdTime=2019-09-20, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=93c21e43356e, moduleTitle=肌层浸润性膀胱癌的治疗：TAR-200在Ib期试验中的阳性结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=93c21e43356e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642045, encodeId=96f616420452b, content=<a href='/topic/show?id=679b9e514c8' target=_blank style='color:#2F92EE;'>#阳性结果#</a>, objectTitle=JAMA:CSF非培养感染检测在免疫功能正常的儿童中很常见，但阳性结果很少, objectType=article, longId=176425, objectId=f06d1e6425ff, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f06d1e6425ff, replyNumber=0, likeNumber=69, createdTime=2020-05-10, rootId=0, userName=12498cb5m20暂无昵称, userId=28fb22837833, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f06d1e6425ff, moduleTitle=JAMA:CSF非培养感染检测在免疫功能正常的儿童中很常见，但阳性结果很少, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f06d1e6425ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

阳性结果

2020-05-29

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

RNAi药物STP705治疗原位皮肤鳞状细胞癌， II期临床试验中期分析获得阳性结果

2020-12-16

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

喜大普奔 | III期FLAURA 研究OS取得阳性结果，EGFR突变晚期非小细胞肺癌一线标准治疗已成定论

2019-11-17

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

Tisotumab Vedotin治疗复发或转移性宫颈癌：II期临床试验取得阳性结果

2021-01-31

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

Enhanze药物输送技术：评估固定剂量皮下注射帕妥珠单抗和曲妥珠单抗的III期试验取得阳性结果

2020-04-13

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

Biogen宣布BDCA2单抗BIIB059在皮肤性红斑狼疮和系统性红斑狼疮的2期研究阳性结果

2020-11-10

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

Kadimastem报告其针对渐冻症的干细胞疗法阳性结果

2020-02-10

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

Antolimab（AK002）治疗肥大细胞胃肠道疾病：I期阳性结果

2020-04-20

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

赛诺菲公布其长效胰岛素Toujeo治疗青少年糖尿病的3期阳性结果

2019-11-29

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

诺华宣布其联合疗法QVM149和QMF149针对不受控的哮喘病患者III期阳性结果

2020-07-18

heli0118 (审核中...)

前往app查看评论内容

#阳性结果#

JAMA：阳性结果的文章，一定更受关注吗？

2020-02-15

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

2019年美国心脏协会科学会议：细胞疗法CLBS16治疗冠状动脉微血管功能障碍取得阳性结果

2020-04-06

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

阳性结果促使埃博拉临床试验提前停止

2020-06-21

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

AP&T：使用基于粪便细菌标记物的特征的检测手法可减少粪便免疫化学测试假阳性结果

2019-12-02

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

Kyowa Hakko Kirin公布其白细胞介素-17受体A单抗brodalumab治疗轴性脊柱关节炎患者的临床3期阳性结果

2020-01-31

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

Terns宣布其血管粘附蛋白-1抑制剂TERN-201治疗非酒精性脂肪性肝炎的I期临床中期阳性结果

2020-01-20

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

辉瑞公布其JAK1口服抑制剂治疗特应性皮炎III期临床的阳性结果

2019-10-26

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

XTANDI治疗转移性激素敏感性前列腺癌患者的III期ARCHES试验取得阳性结果

2019-07-01

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

安进宣布两项三期双特异性抗体BLINCYTO（靶向CD3和CD19）治疗小儿复发性急性淋巴细胞白血病患者的阳性结果

2020-01-18

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

肌层浸润性膀胱癌的治疗：TAR-200在Ib期试验中的阳性结果

2019-09-20

12498cb5m20暂无昵称 (审核中...)

前往app查看评论内容

#阳性结果#

JAMA:CSF非培养感染检测在免疫功能正常的儿童中很常见，但阳性结果很少

2020-05-10

科室
- - 订阅+
  - 更多科室
工具
服务